Mengyuan Yang , Jie Xu , Mengmeng Zhao , Jiaxin Zhou , Yifan Hou , Long Zhao , Fang Liu , Yinjiu Huang
{"title":"Synthesis of quinazoline derivatives and their in vitro inhibition activity against MDA-MB-231 cells and A549 cells","authors":"Mengyuan Yang , Jie Xu , Mengmeng Zhao , Jiaxin Zhou , Yifan Hou , Long Zhao , Fang Liu , Yinjiu Huang","doi":"10.1016/j.bmcl.2025.130308","DOIUrl":null,"url":null,"abstract":"<div><div>A series of novel 4-aniline quinazoline derivatives (<strong>Y1-Y26</strong>) were synthesised from 2-amino-6-nitrobenzoic acid based on the quinazoline parent nucleus via trifluoroacetylation, ring-closing and chlorination; The CCK-8 method was used to assess the in vitro inhibitory activities of the resulting compounds against two distinct cell lines: breast cancer cells (MDA-MB-231) and non-small cell lung cancer (A549). The results demonstrated that most of the compounds exhibited in vitro proliferation inhibitory activity against both MDA-MB-231 and A549 cells. Among these, compound <strong>Y22</strong> exhibited the strongest inhibitory effect on MDA-MB-231 cells (IC<sub>50</sub> = 4.53 μM); As the concentration of <strong>Y22</strong> increased, the inhibition of cell proliferation was enhanced, and the cells gradually shrank and underwent morphological changes consistent with apoptosis; Transwell assay demonstrated that the compound <strong>Y22</strong> exhibited a substantial inhibitory effect on cell migration; Flow cytometry revealed a substantial augmentation in apoptosis with elevated compound concentrations; Western blot analysis indicated that <strong>Y22</strong> may exert in vitro antitumour activity by decreasing the expression of the anti-apoptotic protein Bcl-2 while increasing the expression of the pro-apoptotic protein Bax. The findings of these studies suggest that <strong>Y22</strong> can potentially plays a significant role in the design and synthesis of antitumour drugs.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"127 ","pages":"Article 130308"},"PeriodicalIF":2.5000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic & Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960894X25002173","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
A series of novel 4-aniline quinazoline derivatives (Y1-Y26) were synthesised from 2-amino-6-nitrobenzoic acid based on the quinazoline parent nucleus via trifluoroacetylation, ring-closing and chlorination; The CCK-8 method was used to assess the in vitro inhibitory activities of the resulting compounds against two distinct cell lines: breast cancer cells (MDA-MB-231) and non-small cell lung cancer (A549). The results demonstrated that most of the compounds exhibited in vitro proliferation inhibitory activity against both MDA-MB-231 and A549 cells. Among these, compound Y22 exhibited the strongest inhibitory effect on MDA-MB-231 cells (IC50 = 4.53 μM); As the concentration of Y22 increased, the inhibition of cell proliferation was enhanced, and the cells gradually shrank and underwent morphological changes consistent with apoptosis; Transwell assay demonstrated that the compound Y22 exhibited a substantial inhibitory effect on cell migration; Flow cytometry revealed a substantial augmentation in apoptosis with elevated compound concentrations; Western blot analysis indicated that Y22 may exert in vitro antitumour activity by decreasing the expression of the anti-apoptotic protein Bcl-2 while increasing the expression of the pro-apoptotic protein Bax. The findings of these studies suggest that Y22 can potentially plays a significant role in the design and synthesis of antitumour drugs.
期刊介绍:
Bioorganic & Medicinal Chemistry Letters presents preliminary experimental or theoretical research results of outstanding significance and timeliness on all aspects of science at the interface of chemistry and biology and on major advances in drug design and development. The journal publishes articles in the form of communications reporting experimental or theoretical results of special interest, and strives to provide maximum dissemination to a large, international audience.